4D Molecular TherapeuticsFDMT
Recorded

4D Molecular Therapeutics Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Colleen KusyAnalyst

All right. Good morning, everyone. Welcome to the Stifel Healthcare Conference. My name is Colleen Kusy. I am one of the senior analysts here covering biotech, and this morning, I am very happy to have with us the team from 4DMT, including CFO Kristian Humer and Chief Commercial and Business Officer Chris Simms. They will give a formal presentation, and then we will dive into some Q&A.

Chris SimmsChief Commercial and Business Officer

Awesome. Thank you, Colleen, and good morning. We appreciate the opportunity this morning to share the 4DMT story. My name is Chris Simms, as Colleen mentioned, the Chief Commercial and Business Officer. Just as a note, we may be making some forward-looking statements. More information can be found on our website or in our SEC filings. Some key takeaways for today. First of all, we are really excited at 4DMT with the progress that we have made on our lead program, 4D-150, which is going to take up pretty much the entire presentation today. We have other things in development, but most of our focus right now is on our lead program, 4D-150, and I think the reasons for that will be obvious as I go through the deck. 4D-150 is our lead retina program.

Chris SimmsChief Commercial and Business Officer

We believe it has the potential to establish a new treatment paradigm for the treatment of wet age-related macular degeneration. Some key reasons why we believe that to be possible. First of all, we are pursuing 4D-150 to be a backbone therapy with the potential for lifelong continuous disease control from a single intravitreal dose, an injection. Second, our target product profile, which we will review in a little more detail in a few slides, addresses what we view as the key unmet need of patients in this space, specifically the preservation of vision while reducing treatment burden, with the opportunity for some patients to be injection-free for a lifetime. As we will go through, that is quite a shift from current standard of care and what patients currently experience. The third point is that our clinical trial data, our phase III design, and strong execution positions as well for success.

Chris SimmsChief Commercial and Business Officer

I will touch a little bit more on that as well. The fourth point, really important when it comes to commercial adoption, is that patients, physicians, and payers together are expected to drive, we believe, robust and broad commercial adoption. We believe we have the possibility to address some really important unmet needs across all of these stakeholders, which ultimately will be the foundation for our commercial strategy. Sorry, FYI, the countdown clock is not moving, if that matters. Just as a reminder why we believe we are uniquely positioned to achieve this, let us take a look at the design of 4D-150. It is designed for a low-dose targeted delivery of aflibercept-producing transgenes to the retina with, again, a single intravitreal injection. At the core to our product design is our vector. The R100 capsid was invented and developed at 4DMT.

Chris SimmsChief Commercial and Business Officer

It is proprietary, and we believe that capsid allows us to be very unique in our approach to using the gene therapy for treating retinal disease. Specifically, the R100 vector allows us to do three things that are really important. First of all, it allows us to take a low-dose intravitreal injection approach. Second, it allows us to be targeted in the delivery to retinal tissue specifically. Third, we believe it has the potential for minimal toxicity and inflammation. When we combine the R100 capsid with our payload, specifically the fact that it includes aflibercept, which is commonly known, of course, as EYLEA, which has been dosed in over 64 million eyes since it launched, we think the combination of that provides a direct retina-specific therapeutic effect that has the potential for lifelong expression for patients. Why is that important? Well, just take a moment to consider the biology of wet AMD.

Chris SimmsChief Commercial and Business Officer

Wet AMD is a disease. It is chronic, it is variable, it is heterogeneous, it is always there. The current treatment paradigm today is episodic and finite with bolus injections. These bolus injections work really well. We see that when patients are diagnosed, they often get upfront loading doses of two or three injections, and then they are put on some sort of a schedule of extension based upon the need. It could be a month, it could be every other month, based again on what the physician deems is appropriate. That creates an oscillation and a peak and trough in the treatment of the disease. The challenge with that is that you have a chronic always-on disease, and you have a treatment approach that is episodic. Again, you see those peaks and troughs.

Chris SimmsChief Commercial and Business Officer

What that results in for many patients is, one, a significant treatment burden that is hard to maintain over time. That significant treatment burden often results in the lack of continuous disease control. For many patients, the combination of those two things means that over time, they actually lose vision, which is unfortunate because we know that these therapies, we know that VEGF suppression actually causes a patient to gain vision upon diagnosis. However, the current bolus treatment approach often results in that vision being lost as patients are unable to sustain the treatment burden. We believe a better approach is a backbone therapy. With 4D-150, simply, we take a backbone therapy approach that we believe provides continuous disease control, and we match the therapy with the chronic nature of the disease.

Chris SimmsChief Commercial and Business Officer

The potential for that is illustrated in this next slide, which is, we think it solves for what we refer to as the continuous control gap. The continuous control gap is simply this. As I mentioned, patients lose vision today on current bolus therapies. Despite gaining vision initially, the burden of treatment causes vision to be lost over time. We see that in the real world, somewhat regardless of the durability of the bolus therapy that patients are being treated with. A big piece of development for a lot of new therapies that are trying to enter into this space is increasing the durability by increments. While we know that to be important, we have seen that with historical recent launches, none of these therapies offer the potential of continuous disease control for the life of the patient.

Chris SimmsChief Commercial and Business Officer

We believe with 4D-150 as a backbone therapy, we could control or we could close that continuous control gap, thereby allowing patients the possibility of preserving vision for the rest of their lives, in addition to significantly reducing the burden of treatment. This slide recaps some results from our phase II trial that we've shared previously. Specifically, we look here at the 15 patients that are within the recently diagnosed population. The reason we highlight that patient population being recently diagnosed is that they're most comparable to the patients that we're studying in our phase III program. I'll go through those details in a few minutes. What we see from our PRISM results is actually quite encouraging. Here we see on the left-hand side that out to two years, you see good steady control of central subfield thickness.

Chris SimmsChief Commercial and Business Officer

It's a biomarker, in essence, for anatomical control. That's really important when it comes to treating this disease. Physicians often reference that as a marker for whether they retreat or not. We also see a nice continuous maintenance of visual acuity, as evidenced by the bottom left-hand chart. Back to the slide a couple of minutes ago where we said, closing that continuous control gap requires that you maintain vision to be steady over a long period of time. We actually see that with our phase II results from PRISM. In addition, on the right-hand side, we've been able to deliver that in the context of significant treatment burden reduction. Specifically, again, over two years, patients got an average of 1.6 supplemental injections.

Chris SimmsChief Commercial and Business Officer

If you compare that to what they would have received if they were being treated on-label with EYLEA at a Q8 week frequency, that's an 87% treatment burden reduction. Really importantly, 66% of those patients out to two years were injection-free. Of course, none of this matters if you don't have a safety profile that's acceptable. What we see with the 71 patients that have been treated with the phase III dose is a safety profile that's very encouraging. We had two cases of inflammation early on that were mild and transient and were resolved within the 20-week prophylactic steroid regimen that we administered. After that 20-week period, we saw no cases of 4D-150-related inflammation events. Really importantly, there were no cases of serious adverse events observed at any time point. So no cases of occlusive or non-occlusive retinal vasculitis, choroidal effusions, or endophthalmitis, or hypotony.

Chris SimmsChief Commercial and Business Officer

From a product profile standpoint, to summarize, 4D-150, we believe, is designed to achieve what we view as an ideal product profile that has the potential to be best in class for treating wet AMD by providing a backbone therapy and the possibility of continuous disease control. We've listed the five supporting elements that underpin that value proposition on the right. I won't take you through all of them, but I will point out at the bottom, it's a point I think worth reiterating, which is the fact that 4D-150 is designed to be delivered as a single in-office intravitreal injection. The reason that's really important is that retina clinics are super busy. Often today, retina doctors are administering 50, 60, upwards of 80 bolus injections to patients in an injection clinic. Therefore, a product that fits seamlessly into that process is really important for real-world adoption.

Chris SimmsChief Commercial and Business Officer

Further, the fact that it's a single intravitreal injection from a commercial perspective means that 4D-150 will be reimbursed, we believe, through the buy-and-bill reimbursement model, which is, of course, very familiar to retina clinics today. Just a couple of comments on our phase III program, 4FRONT-1 and 4FRONT-2, a global program designed for global approval. We've had great interaction and supportive interactions with regulatory agencies from the FDA and EMA, where we have RMAT and PRIME designations respectively. We've also had very productive interactions with PMDA. Both trials are fully enrolled and again, powered for the stringent criteria of about four letters of difference in the non-inferiority of vision at week 52.

Chris SimmsChief Commercial and Business Officer

A side note as well, as you'll see on this slide, the majority of patients in these trials are treatment-naive, with an exception of 4FRONT-2, where a portion can be treated up to a maximum of six months. That's really important because I think that's the first time that an intravitreal gene therapy has gone into, in essence, a frontline patient population. The fact that we were able to do that and we enrolled both trials within about a 12-month period, we think is a strong indication of the unmet need and the enthusiasm, both from physicians as well as patients. Just a couple of notes on the trial design. Again, we'll point out that our phase III wet AMD trials are fairly standard designs, so we compare 4D-150 to an on-label control arm of aflibercept with a week 52 endpoint measuring non-inferiority in vision.

Chris SimmsChief Commercial and Business Officer

It's important as well to highlight that we think we've optimized for the patient population. The two bottom green boxes that are highlighted there talks about how we believe we've done that. Specifically, we capped the entry criteria from an anatomical standpoint to 500 microns. In addition to that, we require that patients show at least a 15% reduction in CST or a complete resolution of retinal fluid to get randomized into our trial. That's important for a couple of reasons, but one of the key points is that we believe it helps protect vision, but also reduces variability in the dataset. Of course, the other element of the design, which is fairly common, is that patients are eligible for supplemental treatment. This slide shows the criteria and the reference point that guides the supplemental treatment in our trial.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day